Scientists have uncovered genetic variants that help explain why weight-loss drugs such as Wegovy and Mounjaro work dramatically better for some people than others, according to findings from the journal Nature. A examination involving 15,000 people taking these medications found that those carrying specific gene variations experienced substantially greater weight loss over roughly approximately eight months of treatment. Whilst participants lost an average of 11.7 per cent of their body weight, some shed as much as 30 per cent whilst others noticed little difference. The findings could also provide insight into why certain individuals encounter serious side-effects including nausea and vomiting. Experts suggest the genetic factors, though relatively modest in effect, work alongside other elements such as age, sex and ethnic background to determine how effectively these common weight-management treatments perform.
The genetic discovery revolutionising obesity care
Researchers examining data from 23andMe discovered two key genetic variants that substantially affect how well weight-loss medications work. The first variant, associated with appetite regulation and digestion, is associated with greater weight loss when taking drugs like Wegovy and Mounjaro. People carrying a single copy of this variant lose approximately 0.76 kilogrammes more on average, whilst those with two copies can double that additional weight loss. The variant is especially prevalent among people of European ancestry, with 64 per cent carrying one copy and 16 per cent carrying two, compared to just 7 per cent of African Americans.
The other genetic variant discovered in the study is associated with severe gastrointestinal side-effects when taking tirzepatide, the key component in Mounjaro. Researchers determined that approximately 1 per cent of people carrying this variant develop extremely intense vomiting—nearly 15 times more severe than common side-effects. Professor Ruth Loos from the University of Copenhagen, who discussed the research, emphasised that whilst the genetic influences are fairly modest, they are comparable to other influential factors and should not be dismissed as insignificant in understanding individual drug responses.
- Genetic variants affect weight loss by around 0.76 kilogrammes per person
- European ancestry populations show higher prevalence of weight-loss associated genes
- Second genetic variant increases risk of severe nausea and vomiting
- Genetic factors operate in conjunction with age, sex and ethnicity in establishing effectiveness
How genes influence medication effectiveness
The weight loss approach explained
The primary genetic variant identified in the research affects the body’s hunger control and digestive processes, substantially influencing how weight-loss medications work. Individuals possessing this variant experience greater weight reduction when taking drugs such as Wegovy and Mounjaro, with studies suggesting an additional 0.76 kilogrammes lost on average relative to those without the variant. The mechanism appears linked to how the genes engage with the medications’ appetite-suppressing effects, amplifying their potency in reducing hunger signals and enhancing fullness across the treatment period.
The influence becomes even more marked for those carrying two copies of the genetic variant. These individuals can effectively double their additional weight loss, possibly gaining considerable gains over those with one copy when undertaking weight management therapy. This dual-copy genetic effect amounts to a significant variation in outcomes, particularly important for patients pursuing optimal treatment outcomes. However, researchers emphasise that this genetic advantage comes with a trade-off, as those affected also experience heightened digestive adverse effects, such as nausea and retching throughout therapy.
Heritage and genetic variation
The frequency of this weight-loss-related genetic variant varies considerably across different populations, with ancestry playing a determining role in chances of inheriting it. European ancestry populations exhibit markedly greater carrier rates relative to other ethnic groups, highlighting genetic diversity across global populations. This disparity presents important considerations for tailored medical approaches and clarifying why weight-loss drug efficacy may vary among individuals from different ethnic backgrounds, which may affect treatment planning and outcome expectations.
| Population Group | Percentage Carrying Gene Variant |
|---|---|
| European ancestry (one copy) | 64% |
| European ancestry (two copies) | 16% |
| African American (one copy) | 7% |
| African American (two copies) | Data not specified |
Understanding these hereditary patterns helps clarify observed variations in drug response across diverse groups. The notably elevated prevalence of the weight-loss variant among people of European descent suggests they may experience greater benefits from these drugs on average. Conversely, lower carrier rates in African American communities indicate distinct genetic patterns that may require different treatment approaches or adjusted expectations regarding weight-reduction results with existing obesity treatments.
Beyond genetics: the bigger picture
Whilst genetic variations offer useful understanding into individual drug responses, researchers stress that inherited factors represent only one piece of a considerably larger puzzle. Professor Ruth Loos observes that the genetic effect, though modest, remains “similar to other factors – and not trivial.” This indicates that numerous additional variables influence how successfully weight-loss medications function for each person. Sex, age, lifestyle choices, metabolism and general health condition all play a significant role to treatment outcomes, sometimes outweighing hereditary tendency entirely.
The multifaceted nature of individualized healthcare becomes evident when considering that 15,000 research subjects experienced widely varying weight loss despite receiving identical pharmaceutical treatments. Some reduced by 30 per cent of their total weight over eight months, whilst others saw little change. This striking difference demonstrates that genetics alone cannot determine positive outcomes. External conditions, compliance with treatment regimens, eating patterns and unique biological makeup interact dynamically with genetic blueprints to establish end results, pointing to the need for a tailored method to weight management is essential.
- Sex differences may influence drug metabolism and weight loss outcomes significantly
- Age shapes metabolic rate and medication effectiveness in quantifiable terms
- Ethnic background determines both genetics and environmental health factors
- Lifestyle choices and dietary habits remain crucial despite genetic factors
- Individual medical conditions interact with medication responses in unpredictable ways
Sex, age and ethnicity factors
Sex differences have a significant impact in shaping how weight-loss medications affect individuals, with growing research suggesting men and women may respond differently to drugs like Wegovy and Mounjaro. Hormonal differences, differences in body composition and varying metabolic processes between sexes may affect drug absorption and effectiveness. Age likewise affects treatment success, as older people typically have slower metabolic functioning and may experience different medication processing compared to younger patients, thus impacting weight loss patterns and side-effect magnitude.
Ethnicity encompasses both genetic and socioeconomic dimensions that influence medication outcomes beyond simple genetic inheritance. Cultural dietary patterns, healthcare availability, medication affordability and lifestyle factors differ considerably across ethnic groups, all affecting the effectiveness of weight-loss drugs. Researchers acknowledge that comprehending these overlapping factors necessitates detailed study beyond genetic analysis alone, ensuring that future treatment guidelines cater to diverse populations fairly and effectively.
From research findings to patient care
The discovery of genetic variants influencing weight-loss drug efficacy creates promising avenues for personalised medicine in weight management. Translating these research results into real-world healthcare requires thoughtful evaluation of how genetic screening could be incorporated within NHS prescription guidelines and private medical services. Healthcare professionals may in future use genetic testing to predict which individuals will show the best response to specific medications, possibly enhancing clinical results and minimising unwanted adverse effects. However, introducing such testing across the system presents operational and budgetary challenges that the health service must tackle in a structured manner.
Current obesity treatment continues to be largely one-size-fits-all, with patients being prescribed identical medications irrespective of their genetic makeup. As genetic understanding deepens, clinicians could tailor prescriptions to individual genetic profiles, optimising weight reduction whilst minimising adverse reactions. This shift towards precision medicine requires funding in genetic testing infrastructure, healthcare worker training and updated clinical guidelines. The research indicates that whilst genetic factors contribute modestly, their identification combined with assessment of other variables could substantially improve treatment efficacy and patient satisfaction across diverse populations.
The precision medicine promise
Precision medicine marks a key transformation from standardised treatment protocols towards tailored patient care based on genetic and physical traits. By identifying which patients carry favourable genetic differences, clinicians could optimise medication selection and dosing regimens, consequently improving weight loss outcomes whilst decreasing sickness and vomiting issues. This approach delivers more efficient resource use, improved patient experiences and greater assurance in weight management across the NHS and independent healthcare.
- Genetic screening can determine how individual patients respond to drugs precisely
- Personalised dosing regimens might reduce negative reactions considerably
- Precision approaches improve treatment satisfaction and clinical outcomes significantly
What that signifies for patients now
For the vast numbers of people currently taking weight-loss medications like Wegovy and Mounjaro, these hereditary insights offer valuable understanding into why their results differ so dramatically. Whilst genetic factors represent only a modest influence on treatment success, they work in conjunction with other major factors including sex, age and racial heritage to shape specific responses. Understanding these patterns helps clarify why some patients experience significant weight losses of 30 per cent or more, whilst others see minimal results despite taking equivalent treatments. This knowledge supports the frustration many patients experience when treatments fail to deliver expected benefits, suggesting genetic causes rather than lack of effort play a significant role.
At present, the NHS and private clinics dispense weight-loss drugs without genetic testing, which means patients are given standardised treatment regardless of their personal genetic makeup. Most people taking these medications are often unaware whether they carry genetic variants that could predict their reaction or vulnerability to side-effects like intense nausea. Whilst genetic screening is not currently routinely available through the NHS, this research offers a basis for future bespoke treatment methods. Patients discussing treatment options with healthcare providers can now understand that their genetic makeup may influence outcomes, potentially encouraging more informed conversations about practical expectations and personal risk considerations before beginning medication.